Copyright
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Jan 14, 2022; 10(2): 594-606
Published online Jan 14, 2022. doi: 10.12998/wjcc.v10.i2.594
Published online Jan 14, 2022. doi: 10.12998/wjcc.v10.i2.594
Biologic therapy for Crohn’s disease over the last 3 decades
Ji-Liang Shen, Jia-Sheng Cao, Bin Zhang, Jia-Hao Hu, Sarun Juengpanich, Xu Feng, Department of General Surgery, Sir Run-Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou 310016, Zhejiang Province, China
Zheng Zhou, Jia-Ying Li, Xiao-Ming Liu, Ming-Song Li, Department of Gastroenterology, Nan Fang Hospital, Southern Medical University, Guangzhou 510515, Guangdong Province, China
Ming-Song Li, Department of Gastroenterology, Third Affiliated Hospital of Guangzhou Medical University, Guangzhou 510000, Guangdong Province, China
Author contributions: Shen JL and Feng X designed the study and collected the data; Shen JL, Zhou Z, and Cao JS analyzed and interpreted the data; Zhou Z, Cao JS, Zhang B, Hu JH, Li JY, Liu XM, and Li MS wrote the manuscript; Juengpanich S and Feng X revised the manuscript; all authors made final approval of the version of the manuscript.
Supported by the National Natural Science Foundation of China , No. 81800540 ; and Key Research and Development Project of Zhejiang Province , No. 2018C03083 .
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
PRISMA 2009 Checklist statement: The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Xu Feng, MD, PhD, Surgeon, Department of General Surgery, Sir Run-Run Shaw Hospital, Zhejiang University School of Medicine, No. 3 East Qingchun Road, Hangzhou 310016, Zhejiang Province, China. phoneshe@zju.edu.cn
Received: August 8, 2021
Peer-review started: August 8, 2021
First decision: October 11, 2021
Revised: October 19, 2021
Accepted: December 7, 2021
Article in press: December 7, 2021
Published online: January 14, 2022
Processing time: 156 Days and 11.8 Hours
Peer-review started: August 8, 2021
First decision: October 11, 2021
Revised: October 19, 2021
Accepted: December 7, 2021
Article in press: December 7, 2021
Published online: January 14, 2022
Processing time: 156 Days and 11.8 Hours
Core Tip
Core Tip: We conducted a bibliometric analysis from the top 100 highest-cited original articles to determine knowledge gaps and identify areas of interest of biologic therapy for Crohn’s disease (CD). The 2000s yielded the most influential original articles and saw the most dramatic growth. The United States and Europe contributed the most publications, and the cooperation relationships between them were most frequent. Gastroenterology published the most articles on biologic therapy for CD. Anti-tumor necrosis factor (TNF) biologics and monoclonal antibodies were the most studied topics. These data would provide useful research insights into biologic therapy for CD for clinicians and researchers.